Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Int J Cancer · 2019 · PMC6766871 · PMID 30807645

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the LU299 model, the combination of rogaratinib (50 mg/kg) and docetaxel showed a trend towards superior tumor growth inhibition compared to treatment with docetaxel alone (Figs. 6 a –6 b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.